Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
NCT00230971
Last updated date
ABOUT THIS STUDY
This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus
metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy
through the test-of-cure assessment. Safety evaluations will occur through the treatment and
post-treatment periods and continue through resolution or stability of the adverse event(s).
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Appendicitis, Cholecystitis, Diverticulitis, Intra-Abdominal Abscess, Intra-Abdominal Infection, Peritonitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Clinical diagnosis of complicated intra-abdominal infection that requires surgery within 24 hours.
- Fever plus other symptoms such as nausea, vomiting, abdominal pain.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Cancer
- Medicines that suppress the immune system
- Dialysis
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Appendicitis, Cholecystitis, Diverticulitis, Intra-Abdominal Abscess, Intra-Abdominal Infection, PeritonitisStudy Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
NCT00230971
- Nambour, Queensland
- Cairns,
- Parkville,
- Shanghai,
- Odense,
- Lahti,
- Seinajoki,
- Tampere,
- Marseille,
- Nimes,
- Pierre Benite,
- Saint Denis,
- Bochum,
- Frankfurt,
- Freiburg,
- Heidelberg,
- Leipzig,
- Luebeck,
- Muenster,
- Tuebingen,
- Athens,
- Athens,
- Thessaloniki,
- New Territories,
- Pokfulam,
- Hyderabad, Andhra
- Bhopal,
- Lucknow,
- Mumbai,
- New Delhi,
- Brescia,
- Genova,
- Pavia,
- Rome,
- Udine,
- Vicenza,
- Manila,
- Quezon City,
- Quezon City,
- Almada,
- Coimbra,
- Porto,
- Porto,
- Riyadh,
- Bellville,
- Kuilsriver,
- Parow,
- Pietermaritzburg,
- Pretoria,
- Barcelona,
- Bilbao,
- Madrid,
- Madrid,
- Murcia,
- Bern,
- Geneva,
- Lugano,
- Zurich,
- Changhua,
- Taichung,
- Tainan,
- Taipei,
- Tao-yuan,
- Ankara,
- Istanbul,
- Stockport, Cheshire
- Birmingham,
- Wigan,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brief Title ICMJE | Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI) | ||||||||||||||||||||||||||||||||||||
| Official Title ICMJE | A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection | ||||||||||||||||||||||||||||||||||||
| Brief Summary | This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s). | ||||||||||||||||||||||||||||||||||||
| Detailed Description | Not Provided | ||||||||||||||||||||||||||||||||||||
| Study Type ICMJE | Interventional | ||||||||||||||||||||||||||||||||||||
| Study Phase ICMJE | Phase 4 | ||||||||||||||||||||||||||||||||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||||||||||||||||||||||||||||||||||
| Condition ICMJE |
| ||||||||||||||||||||||||||||||||||||
| Intervention ICMJE |
| ||||||||||||||||||||||||||||||||||||
| Study Arms ICMJE |
| ||||||||||||||||||||||||||||||||||||
| Publications * | Qvist N, Warren B, Leister-Tebbe H, Zito ET, Pedersen R, McGovern PC, Babinchak T. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial. Surg Infect (Larchmt). 2012 Apr;13(2):102-9. doi: 10.1089/sur.2011.048. Epub 2012 Mar 22. | ||||||||||||||||||||||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||||||||||||||||||||||||||||||||
| Recruitment Information | |||||||||||||||||||||||||||||||||||||
| Recruitment Status ICMJE | Completed | ||||||||||||||||||||||||||||||||||||
| Actual Enrollment ICMJE | 473 | ||||||||||||||||||||||||||||||||||||
| Original Enrollment ICMJE | 430 | ||||||||||||||||||||||||||||||||||||
| Actual Study Completion Date ICMJE | September 2008 | ||||||||||||||||||||||||||||||||||||
| Actual Primary Completion Date | September 2008 (Final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||||||||||||||||||||||||||||||||
| Sex/Gender ICMJE |
| ||||||||||||||||||||||||||||||||||||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||||||||||||||||||||||||||||||||
| Accepts Healthy Volunteers ICMJE | No | ||||||||||||||||||||||||||||||||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||||||||||||||||||||||
| Listed Location Countries ICMJE | Australia, China, Denmark, Finland, France, Germany, Greece, Hong Kong, India, Italy, Philippines, Portugal, Saudi Arabia, South Africa, Spain, Switzerland, Taiwan, Turkey, United Kingdom | ||||||||||||||||||||||||||||||||||||
| Removed Location Countries | Czech Republic | ||||||||||||||||||||||||||||||||||||
| Administrative Information | |||||||||||||||||||||||||||||||||||||
| NCT Number ICMJE | NCT00230971 | ||||||||||||||||||||||||||||||||||||
| Other Study ID Numbers ICMJE | 3074A1-315 | ||||||||||||||||||||||||||||||||||||
| Has Data Monitoring Committee | Not Provided | ||||||||||||||||||||||||||||||||||||
| U.S. FDA-regulated Product | Not Provided | ||||||||||||||||||||||||||||||||||||
| IPD Sharing Statement ICMJE | Not Provided | ||||||||||||||||||||||||||||||||||||
| Responsible Party | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||||||||||||||||||||||||||||||||
| Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||||||||||||||||||||||||||||||||
| Collaborators ICMJE | Not Provided | ||||||||||||||||||||||||||||||||||||
| Investigators ICMJE |
| ||||||||||||||||||||||||||||||||||||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | ||||||||||||||||||||||||||||||||||||
| Verification Date | February 2013 | ||||||||||||||||||||||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | |||||||||||||||||||||||||||||||||||||